




# Medicure Inc. Investor Presentation 2026



# Forward Looking Statement



This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for Medicure Inc., business and operational results. By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, product recalls, competition from similar products and other factors including those risks and uncertainties identified above, and those contained in the Company's most recent MD&A and Form 20F.

Medicure Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

# Medicure's 5 Focuses



Medicure is an R&D specialty pharmaceutical and pharmacy company focused on the US market

1. Growing sales of **ZYPITAMAG**<sup>®</sup>
2. Growing sales of **AGGRASTAT**<sup>®</sup>
3. Growing sales of **Marley Drug**<sup>®</sup> E-Commerce pharmacy subsidiary
4. Complete **Phase 3 Trial** of MC-1 for 10 PNPO patients to receive priority review voucher
5. Begin pre-clinical development of **New Chemical Entity** analogues of pyridoxal 5'-phosphate

*Medicure has No Debt*

# Medicure's Growth Strategy



Medicure plans to use its profit to fund R&D and acquisitions

## Short term:

Growth of ZYPITAMAG, AGGRASTAT and Marley Drug pharmacy

## Near term:

Build the Marley Drug pharmacy business through acquisition and partnerships

Use revenue from sale of MC-1 voucher upon approval to accelerate growth

## Long term:



Development of acquired new drugs for large unmet needs

# Medicare's Pharmacy Acquisitions – Why?


- A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug
- A profitable marketing vehicle for other branded drugs
- Saves on high fees to wholesalers and pharmacy benefit managers
- Medicare recently acquired Gateway Medical Pharmacy and West Olympia Pharmacy to build our customer base and for brand expansion



# Key Financial Parameters





# Key Financial Parameters



\* During 2025, 2.04M of cash was used for the purchases of Gateway Medical Pharmacy and West Olympia Pharmacy.

# Key Financial Parameters



\* Earnings Before Interest, Taxes, Depreciation and Amortization

# Medicure's Leadership Team



**Albert D. Friesen**  
President, Chief Executive Officer  
& Chairman of the Board

- Founded Medicure in 1997
- Created and developed multiple companies, including ABI Biotechnology (Apotex Fermentation), The Winnipeg Rh Institute, DiaMedica and Genesys Venture Inc.



**Haaris Uddin**  
Chief Financial Officer

- Joined Medicure in 2022 as CFO
- Responsible for financial reporting activities and oversight of finance systems



**Reuben Saba**  
Vice President,  
Business Development

- VP since 2019
- Joined Medicure in 2014 in Medical Affairs
- PhD in Neurobiology
- Responsible for the development of new business opportunities

# Zypitamag<sup>®</sup>

(pitavastatin) tablets

**\$6.5M**

In 2025

**↑ 5%**

from the prior year

**\$4B**

Statin market

## INDICATION

High Cholesterol

## PRODUCT HIGHLIGHTS

- Improvements over older statins
- Low rates of side effects like muscle pain
- Doesn't interact with other medications
- Once daily low dose with strong LDL reduction

LEARN MORE AT  
[Zypitamag.com](https://www.zypitamag.com)





## Medicare's Pharmacy Subsidiaries & E-Commerce Website

**\$20.3M**

In 2025

**↑ 88%**

from the prior year\*

**\$40B**

Online pharmacy market

### WHAT IS MARLEY DRUG PHARMACY

- A US pharmacy subsidiary licensed to ship FDA approved medications to all 50 states
- Facilitates Medicare selling ZYPITAMAG directly to consumers

### HIGHLIGHTS

- Increased ZYPITAMAG units dispensed by 17% compared to prior year
- Also sells most generic and branded medications
- E-commerce website for easy ordering and refills
- Medicare acquired Gateway Medical Pharmacy and West Olympia Pharmacy in 2025

LEARN MORE AT  
**MarleyDrug.com**



MPH:TSXV

\* Prior year comparison do not include Gateway Medical Pharmacy or West Olympia Pharmacy<sup>1</sup> which were acquired during 2025



# AGGR<sup>^</sup>STAT<sup>®</sup>

(tirofiban hydrochloride) Injection

**\$5.7M**

In 2025

**↓ 29%**

from the prior year

**Only Approved  
Manufacturer of  
the 3.75 MG Bolus  
Vial Format**

MPH:TSXV

## INDICATION

Acute Coronary Syndrome

## PRODUCT HIGHLIGHTS

- Leading IV antiplatelet in its class
- Used in more than 1,000 hospitals
- Three formats of the product available

LEARN MORE AT  
**Aggrastat.com**



medicure<sup>®</sup>

## PHASE 3 CLINICAL STUDY

# Development of MC-1 for Rare Pediatric Disease

Phase 3 study for treatment of rare pediatric disease called PNPO deficiency

- Study involves 10-15 patients in US, Europe and Australia
- Orphan Drug Status and Fast Track Designation
- Study is ongoing
- If approved Medicure is eligible for a priority review voucher (PRV), which can be redeemed or sold
- **Previous PRV's have been sold for over \$75 million** (based on market demand)
- Medicure has significant experience with MC-1 through exploration of other clinical applications



## R&D PIPELINE

# Development of New Chemical Entities

**Medicure acquired intellectual property related to analogues of pyridoxal 5'-phosphate**

- Significant advantages over existing compounds
- Clinical targets have not yet been disclosed
- Targeting large unmet therapeutic needs
- Currently in pre-clinical development



# Thank You for Your Interest

## For Further Information

### Visit our Websites

[Medicure.com](http://Medicure.com)

[AGGRASTAT.com](http://AGGRASTAT.com)

[ZYPITAMAG.com](http://ZYPITAMAG.com)

[Marley Drug.com](http://Marley Drug.com)

### Investor Relations

[ir@medicure.com](mailto:ir@medicure.com)

1-888-435-2220 (Ext. 228)

Follow us on [LinkedIn](#)